OPTICALLY PURE R(-) ALBUTEROL FOR TREATING ASTHMA
    3.
    发明公开
    OPTICALLY PURE R(-) ALBUTEROL FOR TREATING ASTHMA 失效
    OPTICAL PURE R( - )沙丁胺醇哮喘的治疗。

    公开(公告)号:EP0509036A1

    公开(公告)日:1992-10-21

    申请号:EP91902520.0

    申请日:1991-01-04

    申请人: SEPRACOR, INC.

    IPC分类号: A61K31 A61P11

    CPC分类号: A61K31/135

    摘要: L'isomère R(-) optiquement pur d'albutérol, lequel est exempt de l'isomère S(+), est un broncho-dilatateur puissant soulageant les symptômes associés à l'asthme chez les individus asthmatiques. L'invention a trait à un procédé utilisant l'isomère R(-) optiquement pur d'albutérol afin de traiter l'asthme, tout en réduisant au minimum les effets secondaires associés à l'albutérol.

    OPTICALLY PURE R(-) ALBUTEROL FOR TREATING ASTHMA
    7.
    发明授权
    OPTICALLY PURE R(-) ALBUTEROL FOR TREATING ASTHMA 失效
    OPTICAL纯的R( - )哮喘沙丁胺醇一系列的处理

    公开(公告)号:EP0509036B1

    公开(公告)日:1996-03-27

    申请号:EP91902520.5

    申请日:1991-01-04

    申请人: SEPRACOR, INC.

    IPC分类号: A61K31/135

    CPC分类号: A61K31/135

    摘要: The optically pure R(-) isomer of albuterol, which is substantially free of the S(+) isomer, is a potent bronchodilator for relieving the symptoms associated with asthma in individuals. A method is disclosed utilizing the optically pure R(-) isomer of albuterol for treating asthma while minimizing the side effects associated with albuterol.

    (R,R)-FORMOTEROL IN COMBINATION WITH OTHER PHARMACOLOGICAL AGENTS
    9.
    发明公开
    (R,R)-FORMOTEROL IN COMBINATION WITH OTHER PHARMACOLOGICAL AGENTS 审中-公开
    (R,R)-FORMOTEROL in KOMBINATION MIT ANDEREN PHARMAKOLOGISCHEN WIRKSTOFFEN

    公开(公告)号:EP1742625A1

    公开(公告)日:2007-01-17

    申请号:EP05767555.5

    申请日:2005-04-05

    申请人: SEPRACOR, INC.

    摘要: This invention related to methods of treating, preventing and managing various pulmonary diseases or disorders using stereomerically pure (R,R)-formoterol in combination with other pharmacological agents such as leukotriene inhibitors and neurokinin receptor antagonists. Pharmaceutical compositions comprising (R,R)-formoterol and other pharmacological agents are also disclosed.

    摘要翻译: 本发明涉及使用立体异构纯的(R,R) - 福莫特罗与其它药理学试剂如白三烯抑制剂和神经激肽受体拮抗剂联合治疗,预防和治疗各种肺部疾病或病症的方法。 还公开了包含(R,R) - 福莫特罗和其他药理学试剂的药物组合物。

    MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY
    10.
    发明公开
    MELATONIN COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY 审中-公开
    褪黑激素联合治疗,以改善睡眠质量

    公开(公告)号:EP1696959A2

    公开(公告)日:2006-09-06

    申请号:EP04815391.0

    申请日:2004-12-22

    申请人: SEPRACOR, INC.

    摘要: One aspect of the present invention relates to pharmaceutical compositions comprising a sedative agent; and melatonin or a melatonin analog, collectively referred to as 'melatonin agents.' In a preferred embodiment, the sedative agent is eszopiclone. The pharmaceutical compositions of the invention are useful in the treatment of various sleep disorders. In addition, the present invention also relates to a method of treating a patient suffering from a sleep abnormality or insomnia comprising administering a therapeutically effective amount of a pharmaceutical composition of the invention.